Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profiling

Abstract excerpt

Cancer therapy-related cardiovascular toxicity (CTR-CVT) is now recognised as one of the leading causes of long-term morbidity and mortality in cancer patients. To date, potential overlapping cardiotoxicity mechanism(s) across different chemotherapeutic classes have not been elucidated. Doxorubicin, an anthracycline, and Carfilzomib, a proteasome inhibitor, are both known to cause heart failure in some patients....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chemotherapy-induced cardiotoxicity and mitigation
• Share to Histone Deacetylase Inhibitors Research
• Share to Lung Cancer Research Studies